Loading organizations...
Sanity Group develops cannabinoid-based pharmaceuticals and wellbeing products, aiming to unlock the health benefits of the cannabis plant. The company utilizes an interdisciplinary team, integrating expertise from medicine, pharmacy, and biology to research and create diverse therapeutic applications. This scientific approach guides their product development for various health needs.
Founded in 2018 by Finn Hänsel and Fabian Friede, Sanity Group emerged from a shared belief in cannabinoids' potential. Hänsel, an experienced entrepreneur, and Friede, adept at building international businesses, both brought significant experience. Their core insight centered on how cannabinoid applications could enhance individuals' quality of life.
The company serves individuals seeking improved wellbeing and medical professionals exploring cannabinoid therapies. Sanity Group's vision is to establish personalized treatment concepts and advance medical understanding of cannabis. They strive to streamline access, educate healthcare providers, and innovate new dosage forms, fostering broader utilization of cannabinoids for health.
Sanity Group has raised $131.3M across 7 funding rounds.
Sanity Group has raised $131.3M in total across 7 funding rounds.
Sanity Group has raised $131.3M in total across 7 funding rounds.
Sanity Group's investors include Paolo De Luca, CPA (CA), CFA, Casa Verde Capital, HV Capital, Redalpine Venture Partners, Sinai Ventures, TQ Ventures, Vine Ventures LP, Dennis Aogo, Howard Schultz, Justin Mateen, Mario Götze, Black Jays Investments.
Sanity Group has raised $131.3M across 7 funding rounds. Most recently, it raised $16.3M Other Equity in June 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 25, 2024 | $16.3M Venture Round | Paolo DE Luca, CPA (ca), CFA | — | Announced |
| Sep 1, 2022 | $38M Series B | — | Casa Verde Capital, HV Capital, Redalpine Venture Partners, Sinai Ventures, TQ Ventures, Vine Ventures LP, Dennis Aogo, Howard Schultz, Justin Mateen, Mario Götze | Announced |
| Nov 1, 2021 | $4M Series A | — | Casa Verde Capital, HV Capital, Redalpine Venture Partners, TQ Ventures, Dennis Aogo, Mario Götze | Announced |
| Jun 1, 2021 | $44M Series A | — | Redalpine Venture Partners | Announced |
| Oct 1, 2020 | $5M Series U | — | — | Announced |
| Feb 1, 2020 | $22M Series A | — | Black Jays Investments, Casa Verde Capital, HV Capital, Sinai Ventures, TQ Ventures, Vine Ventures LP, Howard Schultz, Justin Mateen, Neil Parikh | Announced |
| May 1, 2019 | $2M Seed | — | HV Capital | Announced |
Sanity Group is a Berlin-based technology-driven health and life-science company specializing in cannabinoid-based pharmaceuticals and consumer health products. It develops innovative cannabinoid medicines and wellness solutions aimed at improving quality of life by leveraging the endocannabinoid system. The company serves patients and consumers across Europe, addressing medical needs with precise, consistent dosing and efficacy in its products. Since its founding in 2018, Sanity Group has demonstrated strong growth, supported by strategic investors and expanding its footprint in the European cannabis market[1][2][3][5].
Founded by Finn Hänsel and Fabian Friede, entrepreneurs with backgrounds in consulting, consumer goods, and tech, Sanity Group emerged from a vision to unlock the health benefits of cannabinoids through science and innovation. Early traction included building a multidisciplinary team of experts in medicine, pharmacy, biology, and law, and establishing a medical advisory board to guide product development and regulatory strategy. The company has also been involved in pioneering pilot projects for regulated cannabis sales, such as retail operations in Switzerland, despite some regulatory challenges in Germany[2][4][7].
Sanity Group rides the growing global trend of medical cannabis legalization and the increasing acceptance of cannabinoids in healthcare and wellness. The timing is favorable due to expanding European regulatory frameworks and rising consumer demand for scientifically validated cannabinoid therapies. Market forces such as increased investment in cannabis biotech, advances in extraction technology, and a shift toward personalized medicine work in Sanity Group’s favor. The company influences the ecosystem by bridging pharmaceutical rigor with consumer health innovation, helping to legitimize and professionalize the European cannabis industry[1][2][7].
Looking ahead, Sanity Group is poised to expand its leadership in European cannabinoid pharmaceuticals and consumer health markets. Trends shaping its journey include ongoing regulatory evolution, increased clinical research validating cannabinoid therapies, and broader societal acceptance of cannabis-based products. The company’s influence may grow as it continues to pioneer pilot projects, scale product offerings, and deepen partnerships. Its dual focus on medical and consumer segments positions it well to capitalize on the convergence of health tech, biotech, and wellness trends, potentially becoming a cornerstone of Europe’s emerging cannabis ecosystem[2][7].
